<DOC>
	<DOCNO>NCT01487109</DOCNO>
	<brief_summary>This study conduct evaluate safety efficacy treatment CTP-499 24 week patient chronic kidney disease , Type 2 diabetic nephropathy currently receive treatment angiotensin convert enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Efficacy CTP-499 Type 2 Diabetic Nephropathy Patients</brief_title>
	<detailed_description>There two part study , part include double-blind treatment either CTP-499 placebo . Part 1 evaluate safety efficacy treatment CTP-499 twice daily 24 week . Part 2 evaluate effect long term dose additional 24 week . Following Part 2 , patient allow participate Open Label extension CTP-499 period additional 48 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Male female 18 year old Patient diagnose Type 2 diabetes mellitus chronic kidney disease On stable regimen ACE inhibitor and/or ARB drug minimum 4 week Not expect start dialysis one year Patient blood pressure less equal 145/90 mm Hg Patient UACR great equal 200 mg/g male 300 mg/g female 5000 mg/g Patient glycosylated hemoglobin A1c le equal 10.5 % Patient concurrent condition uncontrolled inflammatory disease , acute infection unstable illness Patient history allergy sensitivity pentoxifylline methylxanthines Patient acute , active and/or unstable renal impairment hospitalize acute renal failure within previous year Patient active malignancy history neoplastic disease Patient QTc interval great 450 millisecond Patient ALT AST great 3 time upper limit normal potassium great equal 5.5mEq/L screen Patient breast feeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>